• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Trends in PCSK9 inhibitor utilization in the United States, Europe, and other countries: An analysis of international sales data.

作者信息

Blais Joseph Edgar, Wei Yue, Knapp Martin, Wong Ian C K, Wei Li, Chan Esther W

机构信息

Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.

Care Policy and Evaluation Centre, Department of Health Policy, London School of Economics and Political Science, London, UK.

出版信息

Am Heart J. 2022 Jun;248:13-20. doi: 10.1016/j.ahj.2022.02.008. Epub 2022 Mar 1.

DOI:10.1016/j.ahj.2022.02.008
PMID:35240102
Abstract
摘要

相似文献

1
Trends in PCSK9 inhibitor utilization in the United States, Europe, and other countries: An analysis of international sales data.美国、欧洲及其他国家前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂的使用趋势：国际销售数据分析
Am Heart J. 2022 Jun;248:13-20. doi: 10.1016/j.ahj.2022.02.008. Epub 2022 Mar 1.
2
Trends in Lipid-Lowering Agent Consumption in Croatia: A 25-Year Observational Study.克罗地亚降脂药物消费趋势：一项为期25年的观察性研究。
Pharmacol Res Perspect. 2025 Jun;13(3):e70122. doi: 10.1002/prp2.70122.
3
Cost-effectiveness evaluation of the use of PCSK9 inhibitors.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂使用的成本效益评估
Endocrinol Diabetes Nutr (Engl Ed). 2021 Jun-Jul;68(6):369-371. doi: 10.1016/j.endien.2021.05.003. Epub 2021 Oct 26.
4
Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.医疗保险受益人群中低密度脂蛋白胆固醇降低疗法的使用和成本趋势：来自医疗保险部分 D 数据库的分析。
JAMA Cardiol. 2021 Jan 1;6(1):92-96. doi: 10.1001/jamacardio.2020.3723.
5
Assessment and Management of Patients with Hyperlipidemia Referred for Initiation of PCSK9 Inhibitor Therapy: A Lipid Clinic Experience.血脂异常患者启动 PCSK9 抑制剂治疗的评估与管理：脂科门诊经验。
Am J Cardiovasc Drugs. 2019 Dec;19(6):553-559. doi: 10.1007/s40256-019-00352-6.
6
Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition.血清前蛋白转化酶枯草溶菌素9型（PCSK9）的变异、心血管疾病风险以及PCSK9抑制潜在意外效应的研究
Circ Genom Precis Med. 2019 Jan;12(1):e002335. doi: 10.1161/CIRCGEN.118.002335.
7
New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines.高胆固醇治疗的新疗法：回归基于目标的血脂指南的理由。
JAMA. 2015 Oct 13;314(14):1443-4. doi: 10.1001/jama.2015.10017.
8
Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis.降血脂药物治疗高胆固醇血症患者的疗效和安全性比较：一项频率学派网状Meta分析。
Medicine (Baltimore). 2019 Feb;98(6):e14400. doi: 10.1097/MD.0000000000014400.
9
Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies.PCSK9 抑制剂降脂治疗的增量净效益：成本效益研究的系统评价和荟萃分析。
Eur J Clin Pharmacol. 2022 Mar;78(3):351-363. doi: 10.1007/s00228-021-03242-6. Epub 2021 Oct 27.
10
The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia.LDLR c.501C＞A 是家族性高胆固醇血症的致病变异。
Lipids Health Dis. 2021 Sep 12;20(1):101. doi: 10.1186/s12944-021-01536-3.

引用本文的文献

1
Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability.欧洲生物制药的引入：早期扩散模式与数据可用性的横断面研究
BioDrugs. 2025 Aug 8. doi: 10.1007/s40259-025-00732-2.
2
Current and future role of PCSK9 inhibitors in ASCVD prevention.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂在动脉粥样硬化性心血管疾病（ASCVD）预防中的当前及未来作用
Future Cardiol. 2025 Feb;21(2):71-73. doi: 10.1080/14796678.2025.2450189. Epub 2025 Jan 5.
3
Real-World safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia.
依洛尤单抗在沙特阿拉伯原发性高胆固醇血症和混合性血脂异常患者中的真实世界安全性和有效性
Saudi Pharm J. 2024 Dec;32(12):102203. doi: 10.1016/j.jsps.2024.102203. Epub 2024 Nov 4.
4
The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias.血脂异常管理中获取新兴疗法的障碍及潜在解决方案
J Clin Med. 2024 Jul 16;13(14):4160. doi: 10.3390/jcm13144160.
5
Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.意大利基于 AIFA 监测登记处的回顾性队列研究：PCSK9 抑制剂降低家族性高胆固醇血症患者 LDL-C 的真实世界疗效。
J Am Heart Assoc. 2023 Nov 7;12(21):e026550. doi: 10.1161/JAHA.122.026550. Epub 2023 Oct 18.
6
Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications.基于真实世界数据影响探讨亚洲使用前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂的挑战。
J Atheroscler Thromb. 2023 Sep 1;30(9):1106-1107. doi: 10.5551/jat.ED230. Epub 2023 Mar 22.
7
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance.PCSK9 抑制剂在心血管风险管理中的应用：实用指南。
Vasc Health Risk Manag. 2022 Jul 20;18:555-566. doi: 10.2147/VHRM.S275739. eCollection 2022.